Literature DB >> 12760877

Chlamydia pneumoniae resists antibiotics in lymphocytes.

Hiroyuki Yamaguchi1, Herman Friedman, Mayumi Yamamoto, Keigo Yasuda, Yoshimasa Yamamoto.   

Abstract

Chlamydia pneumoniae infection of lymphocytes in blood has been well documented, and it is apparent that control of this pathogen in these cells may be critical in the development of chronic inflammatory diseases associated with infection by this bacterium. The activity of antibiotics against C. pneumoniae in lymphocytes was assessed in this study by utilizing an in vitro infection model with lymphoid cells. The results obtained indicated that although all of the antibiotics tested showed remarkable activity against bacterial growth in epithelial cells, C. pneumoniae in lymphocytes was less susceptible to antibiotics than was bacterial growth in epithelial cells, which are widely used for the evaluation of anti-C. pneumoniae antibiotics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12760877      PMCID: PMC155834          DOI: 10.1128/AAC.47.6.1972-1975.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Analysis of Chlamydia pneumoniae growth in cells by reverse transcription-PCR targeted to bacterial gene transcripts.

Authors:  Shusaku Haranaga; Hideaki Ikejima; Hiroyuki Yamaguchi; Herman Friedman; Yoshimasa Yamamoto
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model.

Authors:  A Kutlin; C Flegg; D Stenzel; T Reznik; P M Roblin; S Mathews; P Timms; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

3.  Seroprevalence of Chlamydia pneumoniae in the normal population.

Authors:  M V Stolk-Engelaar; M F Peeters
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

4.  Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae.

Authors:  P M Roblin; W Dumornay; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

5.  Antibiotic therapy in coronary heart disease--where do we currently stand?

Authors:  V Anand; S Gupta
Journal:  Cardiovasc Drugs Ther       Date:  2001       Impact factor: 3.727

6.  Detection of Chlamydophila pneumoniae DNA in peripheral blood mononuclear cells of blood donors in the north-east of Italy.

Authors:  M Rassu; F M Lauro; S Cazzavillan; E Bonoldi; M Belloni; M C Bettini; A Pilotto; C Mengoli; A Peron; R Zambello; M Scagnelli; G Bertoloni
Journal:  Med Microbiol Immunol       Date:  2001-12       Impact factor: 3.402

7.  Detection of Chlamydia pneumoniae antigenin PBMNCs of healthy blood donors.

Authors:  S Haranaga; H Yamaguchi; G F Leparc; H Friedman; Y Yamamoto
Journal:  Transfusion       Date:  2001-09       Impact factor: 3.157

8.  Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.

Authors:  Andrei Kutlin; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

9.  A Chlamydia pneumoniae infection model using established human lymphocyte cell lines.

Authors:  Hiroyuki Yamaguchi; Shusaku Haranaga; Herman Friedman; Jo A Moor; Karl E Muffly; Yoshimasa Yamamoto
Journal:  FEMS Microbiol Lett       Date:  2002-11-05       Impact factor: 2.742

10.  Chlamydia pneumoniae seroprevalence in immunocompetent and immunocompromised populations in Milan.

Authors:  F Blasi; R Cosentini; M C Schoeller; A Lupo; L Allegra
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

View more
  6 in total

Review 1.  A review on antiviral activity of the Himalayan medicinal plants traditionally used to treat bronchitis and related symptoms.

Authors:  Rahila Amber; Muhammad Adnan; Akash Tariq; Sakina Mussarat
Journal:  J Pharm Pharmacol       Date:  2016-12-01       Impact factor: 3.765

2.  Chlamydia trachomatis L2/434/Bu Favors Hypoxia for its Growth in Human Lymphoid Jurkat Cells While Maintaining Production of Proinflammatory Cytokines.

Authors:  Ryoya Tsujikawa; Jeewan Thapa; Torahiko Okubo; Shinji Nakamura; Saicheng Zhang; Yoshikazu Furuta; Hideaki Higashi; Hiroyuki Yamaguchi
Journal:  Curr Microbiol       Date:  2022-07-20       Impact factor: 2.343

3.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

4.  Chlamydia pneumoniae growth inhibition in cells by the steroid receptor antagonist RU486 (mifepristone).

Authors:  Hiroyuki Yamaguchi; Shigeru Kamiya; Tomonori Uruma; Takako Osaki; Haruhiko Taguchi; Tomoko Hanawa; Minoru Fukuda; Hayato Kawakami; Hajime Goto; Herman Friedman; Yoshimasa Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

5.  A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication.

Authors:  Dustin L Johnson; Chris B Stone; David C Bulir; Brian K Coombes; James B Mahony
Journal:  BMC Microbiol       Date:  2009-10-14       Impact factor: 3.605

Review 6.  Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease.

Authors:  Steven A Harris; Elizabeth A Harris
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.